Clinical Trial Update: A Phase 1 Dose Escalation Study of IPI-493 [Phase 1]

View source ↗

Summary

A Phase 1 dose-escalation trial of IPI-493 in patients with advanced cancers has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• IPI-493

Snippet

Sponsor: Infinity Pharmaceuticals, Inc. | Conditions: Advanced Malignancies | Phase 1 | Status: TERMINATED